Staging liver fibrosis in chronic hepatitis B with T1 relaxation time index on gadoxetic acid‐enhanced MRI: Comparison with aspartate aminotransferase‐to‐platelet ratio index and FIB‐4
- 26 August 2016
- journal article
- research article
- Published by Wiley in Journal of Magnetic Resonance Imaging
- Vol. 45 (4) , 1186-1194
Abstract
Purpose: To assess the accuracy of the T1 relaxation time index on gadoxetic acid‐enhanced magnetic resonance imaging (MRI) for staging liver fibrosis in chronic hepatitis B (CHB), in comparison and combination with the aspartate aminotransferase‐to‐platelet ratio index (APRI) and fibrosis‐4 (FIB‐4).Materials and Methods: A retrospective study of gadoxetic acid‐enhanced T1 mapping and serum biochemical tests was performed on 126 CHB patients who underwent gadoxetic acid‐enhanced 1.5T MRI, and the histological score used as the gold standard. The reduction rate of T1 relaxation time before and 20 minutes after gadoxetic acid injection (ΔT1, ΔR1%), the contrast uptake rate (KHep), APRI, and FIB‐4 were calculated. The diagnostic efficacy of ΔT1, ΔR1%, KHep, APRI, and FIB‐4 for predicting stage 2 or greater (≥S2), stage 3 or greater (≥S3), and stage 4 (S4) was compared.Results: ΔT1 (r = −0.513, P < 0.001), ΔR1% (r = −0.626, P < 0.001), KHep (r = −0.527, P < 0.001), APRI (r = 0.519, P < 0.001), and FIB‐4 (r = 0.476, P < 0.001) correlated significantly with fibrosis stages. Areas under the curves (AUCs) of ΔR1% for detecting ≥S2, ≥S3, and S4 were 0.849, 0.827, and 0.809, which were greater than that of APRI (0.763, 0.745, 0.787) and FIB‐4 (0.727, 0.738, 0.772), but significant difference was found only in discriminating ≥S2 between ΔR1% and FIB‐4 (P = 0.027). The combination of all five indices performed best, with AUC, sensitivity, and specificity of 0.860, 87.21%, and 72.50% for diagnosing ≥S2, 0.878, 82.81%, and 85.48% for ≥S3, and 0.867, 80.00%, and 83.95% for S4.Conclusion: The gadoxetic acid‐enhanced T1 relaxation time index appears to be superior to APRI and FIB‐4 for predicting hepatic fibrosis. The combined use of gadoxetic acid‐enhanced T1 mapping, APRI, and FIB‐4 may be more reliable for staging liver fibrosis in CHB.Level of Evidence: 4J. Magn. Reson. Imaging 2017;45:1186–1194Keywords
Funding Information
- National Natural Science Foundation of China (81571661)
This publication has 37 references indexed in Scilit:
- Primovist, Eovist: What to expect?Journal of Hepatology, 2012
- MR prediction of liver fibrosis using a liver‐specific contrast agent: Superparamagnetic iron oxide versus Gd‐EOB‐DTPAJournal of Magnetic Resonance Imaging, 2012
- Staging liver fibrosis by using liver-enhancement ratio of gadoxetic acid-enhanced MR imaging: comparison with aspartate aminotransferase-to-platelet ratio indexMagnetic Resonance Imaging, 2011
- Quantifying differences in hepatic uptake of the liver specific contrast agents Gd-EOB-DTPA and Gd-BOPTA: a pilot studyEuropean Radiology, 2011
- Liver biopsy†Hepatology, 2009
- Decreased Expression of Cytochromes P450 1A2, 2E1, and 3A4 and Drug Transporters Na+-Taurocholate-Cotransporting Polypeptide, Organic Cation Transporter 1, and Organic Anion-Transporting Peptide-C Correlates with the Progression of Liver Fibrosis in Chronic Hepatitis C PatientsDrug Metabolism and Disposition, 2008
- Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfectionHepatology, 2006
- A Simple Noninvasive Index Can Predict Both Significant Fibrosis and Cirrhosis in Patients With Chronic Hepatitis CHepatology, 2003
- Water diffusion and exchange as they influence contrast enhancementJournal of Magnetic Resonance Imaging, 1997
- Classification of chronic viral hepatitis: a need for reassessmentJournal of Hepatology, 1991